Price II, W. Nicholson; Rai, Arti K. - 2021
. We argue that the key cause is pervasive trade secrecy in the complex area of biologics manufacturing. Under the current … regime, this trade secrecy, combined with certain features of FDA regulation, not only creates high barriers to entry of … information disclosure to originator manufacturers would leverage the existing interaction of trade secrecy and the regulatory …